JP2022501355A5 - - Google Patents

Info

Publication number
JP2022501355A5
JP2022501355A5 JP2021515150A JP2021515150A JP2022501355A5 JP 2022501355 A5 JP2022501355 A5 JP 2022501355A5 JP 2021515150 A JP2021515150 A JP 2021515150A JP 2021515150 A JP2021515150 A JP 2021515150A JP 2022501355 A5 JP2022501355 A5 JP 2022501355A5
Authority
JP
Japan
Prior art keywords
composition according
erdafitinib
fgfr
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021515150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501355A (ja
JP7761485B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/075222 external-priority patent/WO2020058432A1/en
Publication of JP2022501355A publication Critical patent/JP2022501355A/ja
Publication of JP2022501355A5 publication Critical patent/JP2022501355A5/ja
Application granted granted Critical
Publication of JP7761485B2 publication Critical patent/JP7761485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021515150A 2018-09-21 2019-09-19 胆管癌の処置 Active JP7761485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734501P 2018-09-21 2018-09-21
US62/734,501 2018-09-21
PCT/EP2019/075222 WO2020058432A1 (en) 2018-09-21 2019-09-19 Treatment of cholangiocarcinoma

Publications (3)

Publication Number Publication Date
JP2022501355A JP2022501355A (ja) 2022-01-06
JP2022501355A5 true JP2022501355A5 (cg-RX-API-DMAC7.html) 2022-09-22
JP7761485B2 JP7761485B2 (ja) 2025-10-28

Family

ID=68289904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515150A Active JP7761485B2 (ja) 2018-09-21 2019-09-19 胆管癌の処置

Country Status (15)

Country Link
US (1) US12133851B2 (cg-RX-API-DMAC7.html)
EP (1) EP3852756A1 (cg-RX-API-DMAC7.html)
JP (1) JP7761485B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210064274A (cg-RX-API-DMAC7.html)
CN (1) CN112739347A (cg-RX-API-DMAC7.html)
AU (1) AU2019342289A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005271A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190826A1 (cg-RX-API-DMAC7.html)
IL (1) IL281595A (cg-RX-API-DMAC7.html)
JO (1) JOP20210052A1 (cg-RX-API-DMAC7.html)
MA (1) MA53655A (cg-RX-API-DMAC7.html)
MX (1) MX2021003320A (cg-RX-API-DMAC7.html)
PH (1) PH12021550628A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102546XA (cg-RX-API-DMAC7.html)
WO (1) WO2020058432A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19802377A1 (de) * 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CN114984013A (zh) * 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer
CA3100422A1 (en) * 2018-05-16 2019-11-21 Debiopharm International, S.A. Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3

Similar Documents

Publication Publication Date Title
Chuk et al. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
Kim et al. Bisphosphonates induce senescence in normal human oral keratinocytes
Yamamoto et al. A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors
US20230130243A1 (en) Method of Treating Urothelial Carcinoma and Other Genitourinary Malignancies Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
van Doorn et al. Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects
JP2017503823A (ja) プリドピジンの調節放出製剤
JP2020521794A5 (cg-RX-API-DMAC7.html)
Modi et al. Effect of food on the pharmacokinetics of osmotic controlled‐release methylphenidate HCl in healthy subjects
JP6410795B2 (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
KR20050044587A (ko) B형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도
RU2753523C2 (ru) УЛУЧШЕННЫЙ ТЕРАПЕВТИЧЕСКИЙ ИНДЕКС ИНГИБИТОРОВ ПРОТИВ ИММУННОЙ КОНТРОЛЬНОЙ ТОЧКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ, ВКЛЮЧАЮЩЕЙ ЭКСТРАКТ PHY906, ЭКСТРАКТ Scutellaria baicalensis Georgi (S) ИЛИ СОЕДИНЕНИЕ ИЗ ТАКИХ ЭКСТРАКТОВ
Mooss et al. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia
JP2022546550A5 (cg-RX-API-DMAC7.html)
Krens et al. Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
KR20200058108A (ko) IRE1α 또는 XBP1의 활성 억제제를 유효성분으로 포함하는 항암제 민감성 증진용 약학적 조성물
EA013813B1 (ru) Применение иматиниба для лечения гепатита с
Sakaguchi et al. Effectiveness of additional immunosuppressive drugs for corticosteroid-refractory immune checkpoint inhibitor-induced myocarditis: two case reports
Creasey et al. Pharmacokinetics of captopril in elderly healthy male volunteers
WO2016112381A1 (en) Restoring physiology in iron-deficient organisms using small molecules
WO2021175432A1 (en) Method for administration of an anti cancer agent
Gao et al. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz)
JP2024507221A5 (cg-RX-API-DMAC7.html)
JP2024521696A5 (cg-RX-API-DMAC7.html)
Greenblatt et al. Lidocaine plasma concentrations following administration of intraoral lidocaine solution
JP2023538065A5 (cg-RX-API-DMAC7.html)